Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Similac Advance

This article was originally published in The Tan Sheet

Executive Summary

Ross Products' DHA-, ARA-fortified infant formula will be marketed under Martek Bioscience's GRAS affirmation, granted in May, for algae-derived fatty acids, both companies confirmed. Abbott Labs division's own GRAS petition for tuna-derived DHA, filed Jan. 2, is still pending at FDA, contrary to a report in 1"The Tan Sheet" Feb. 25, 2002, In Brief...

You may also be interested in...



Similac Advance

Ross Products' infant formula fortified with Martek Biosciences' DHA, ARA fatty acid oils will be available by mid-April in food, drug, mass stores, Abbott Labs division says. Advance will come in 12.9 oz. and 25.7 oz. powder, 32 oz. ready-to-feed plastic bottle; formula will be priced at 15% premium over existing products. Ross says it has received FDA clearance for its GRAS petition, submitted Jan. 2; firm will be second to market fortified formula in the U.S. following Mead Johnson's launch of Enfamil LIPIL, reaching shelves this month (1"The Tan Sheet" Jan. 14, 2002, p. 3)...

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel